The Biomedical Translation Bridge program, delivered by MTPConnect is a $22.3 million Medical Research Future Fund initiative, that provided up to $1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to the proof of concept stage.
The BTB program aimed to:
- De-risk and develop ventures so that they can attract further funding opportunities
- Nurture and mentor the next generation of health and medical research innovators in Australia
- Develop ventures to become attractive to the Biomedical Translation Fund (BTF)
- Assist in the development of ventures that aim to ultimately result in preventative interventions, cures and
- Treatments for diseases that address health problems of national significance.
The BTB program was delivered through mentoring and commercialisation advice provided by BTB partners BioCurate (University of Melbourne and Monash University), UniQuest (University of Queensland through its drug discovery initiative QEDDI), the Medical Device Partnering Program (MDPP, led by Flinders University), and the Bridge and BridgeTech programs (Queensland University of Technology) - all pre-eminent organisations engaged in the translation and commercialisation of health and medical research.
21 projects were funded by the BTB program - to view the BTB funded projects from Rounds 1, 2 & 3, expand the right menu.
For more information, contact the BTB Senior Program Manager Dr Amelia Vom.
A Bridge to Commercialisation – the BTB Program’s real and successful project outcomes
Through a series of case studies, the Biomedical Translation Bridge Impact Report highlights the many successes the BTB funded projects have had developing new therapies, technologies and medical devices – from an anti-viral nasal spray already on sale in 30 countries and a “smart” human-grade bionic implant that treats the symptoms of Parkinson’s disease, to identifying a novel preclinical development candidate for the treatment of prostate cancer and developing and manufacturing a patient isolation hood for use in hospitals for COVID-19 and infectious diseases.
The BTB program successfully achieved its key objective to “nurture, de-risk and develop competitive ventures that are attractive for further funding opportunities” and delivered real outcomes:
- 29 new technologies invented or progressed
- seven new products launched
- 56 new jobs created
Through the $22.3 million BTB program, and with industry contributions and substantial amounts of external development capital raised, a total of $156.4 million has been injected into Australia’s MTP sector.
BioCurate is a bold, collaborative venture, dedicated to delivering benefits to the community by helping to advance Australian research and innovation globally. Jointly formed by the University of Melbourne and Monash University, with support from the Victorian State Government, BioCurate was specifically created to invest in, manage and commercialise innovative Australian medical research. We provide a critical bridge between academia and industry by identifying promising research and accelerating its development for real-world clinical impact, while ensuring scientific and commercial rigour. Our multi-disciplinary team has an extensive global network and a proven track record in producing commercially successful therapies, positioning BioCurate well to drive the most feasible commercial pathway forward and improve people’s lives.”
Visit Biocurate for more information.
UniQuest is a leading university-based commercialisation company, managing the intellectual property (IP) of The University of Queensland (UQ). UniQuest has facilitated more than 100 start-up companies built on UQ IP, a milestone unsurpassed by any other Australian university. These companies have gone on to raise more than $776M to take UQ technologies to market. The Queensland Emory Drug Discovery Initiative (QEDDI), a division of UniQuest, is a small molecule drug discovery and development facility translating The University of Queensland and collaborator’s biomedical research into new medicines to deliver faster health benefits. UniQuest is a partner on the MRFF Targeted Translation Research Accelerator (TTRA) Program with MTPConnect.
Visit UniQuest for more information.
Medical Device Partnering Program (MDPP)
The Medical Device Partnering Program, led by Flinders University, runs an ideas incubator driving entrepreneurial culture within the medtech sector. The Program fosters collaborations between researchers, industry, end-users and government and develops novel medical devices with global market potential. It forms the essential links between clinical need and knowledge with technical expertise and industry know-how. MDPP is also a partner on the MRFF Targeted Translation Research Accelerator (TTRA) Program and the Researcher Exchange and Development within Industry (REDI) initiative with MTPConnect.
Visit MDPP for more information.
Bridge and BridgeTech programs (Queensland University of Technology)
The Bridge Program provides commercialisation training focused on the development of new pharmaceuticals in collaboration with a number of partners including universities and leading pharmaceutical companies. Similarly, the BridgeTech Program provides commercialisation training for researchers and entrepreneurs with a focus on the medtech sector in partnership with Australian universities, medtech companies and industry partners. The BridgeTech and Bridge Program, now in their fourth and fifth year respectively, select up to 100 participants annually from around Australia to take part in these fully-supported training programs. The Bridge and BridgeTech Program is also a partner on the MRFF Researcher Exchange and Development within Industry (REDI) initiative with MTPConnect.
Visit the Bridge Program to learn more about pharmaceutical commercialisation.
Visit the BridgeTech Program for more information about medtech commercialisation.
- 6 September 2022 - A Bridge to Commercialisation - Part 1 live from the BTB Finale with Chair Sue MacLeman, the Hon. Robyn Preston MP and some of the team behind the Medihood McMonty
- 31 May 2022 - Dimerix investigates new treatment for COVID-19 complications with Dimerix Bioscience's Dr Robert Shepherd
- 22 November 2021 - LBT Innovations’ Technology Aims to Speed Up Detection of Antimicrobial Resistance with LBT Innovations' Brent Barnes (for World AMR Awareness Week 2021)
- 5 March 2021 - Spotlight: Starpharma’s COVID-19 Nasal Spray for UK & Europe with Starpharma's Dr Jackie Fairley
- 13 August 2020 - South Australia’s Novel Response to Coronavirus with Vaxine's Professor Nikolai Petrovsky
- 7 February 2020 - Funding on Offer Through the Biomedical Translation Bridge Program - Live Round 2 Information Session at the Melbourne Convention and Exhibition Centre
- 14 June 2019 - The Lowdown – everything you need to know about the Biomedical Translation Bridge program - Live Round 1 Information Session at the Victorian Comprehensive Cancer Centre (VCCC) in Melbourne